As interleukin-6 (IL-6) is a critical cytokine in CS-induced mortality in patients receiving engineered T cell therapy, it was first suggested as a potential therapeutic target for COVID-19 CS. This evidence concerns the gene IL6 and Cowden syndrome 1.